Neuropathy is a common complication of diabetes and an initiating factor for foot ulceration. Several medications are available to treat diabetic neuropathic pain, including, antidepressants and anticonvulsant drugs. Additionally, pregabalin, gabapentin and sodium valproate are also considered for diabetic neuropathy pain treatment. Several clinical trials are ongoing to study the impact of drugs such as amitriptyline, desipramine and imipramine for the management of diabetic neuropathic pain.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing diabetic neuropathic pain pipeline development activities are covered. Moreover, diabetic neuropathic pain collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
The treatment for diabetic neuropathic pain includes oral medications such as antidepressants and anticonvulsant drugs. Pregabalin is also prescribed for the treatment of diabetic neuropathic pain as per the guidelines issued by the American Academy of Neurology and the American Academy of Physical Medicine and Rehabilitation. Additionally, gabapentin and sodium valproate are also given for diabetic neuropathy pain management. After several clinical evaluations, gabapentin proved a significant pain relief in patients suffering from chronic neuropathic pain.
Other drugs given to treat the condition include dextromethorphan, tramadol, morphine sulfate, and oxycodone. To patients, where oral medications are a concern, topical therapy with capsaicin or transdermal lidocaine are useful. In clinical trials, capsaicin has been proven effective in reducing pain associated with diabetic neuropathic. In some other clinical trials, duloxetine's effects on painful diabetic peripheral neuropathy were studied and showed positive results in the reduction of pain. These increasing clinical trials and changing dynamics are impacting the diabetic neuropathic pain clinical trial landscape significantly.
This product will be delivered within 3-5 business days.
Report Coverage
The Diabetic Neuropathic Pain Drug Pipeline Report by the publisher gives comprehensive insights into ongoing diabetic neuropathic pain clinical trials. It covers various aspects related to the details of diabetic neuropathic pain drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The diabetic neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from spinal fusion.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing diabetic neuropathic pain pipeline development activities are covered. Moreover, diabetic neuropathic pain collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Diabetic Neuropathic Pain Drug Pipeline Outlook
Diabetic a common complication of diabetes. It affects as many as 50% of people suffering from type 1 and type 2 diabetes and involves the signs of peripheral nerve dysfunction in people suffering from diabetes. Distal polyneuropathy becomes symptomatic in type 1 diabetes after long years of chronic prolonged hyperglycemia. While in type 2 diabetes, it is apparent after a few years of poor glycemic control, or even at diagnosis. Its symptoms include distal or more focal weakness and affects the gastrointestinal, cardiovascular, among others. There are four types of diabetes-related neuropathy including peripheral, proximal, autonomic, and focal. Peripheral neuropathy usually affects the legs and feet, and autonomic neuropathy affects the digestive system but can also affect the blood vessels, and urinary. Proximal neuropathy affects thighs, hips, or buttocks and focal neuropathy affects specific nerves in the head, torso, or leg. The diagnosis of diabetic neuropathy can be done through laboratory tests which include hemoglobin A1c, thyroid function tests, vitamin B-12 and folate levels, C-reactive protein, rapid plasma regain, erythrocyte sedimentation rate, and antinuclear antibody among others.The treatment for diabetic neuropathic pain includes oral medications such as antidepressants and anticonvulsant drugs. Pregabalin is also prescribed for the treatment of diabetic neuropathic pain as per the guidelines issued by the American Academy of Neurology and the American Academy of Physical Medicine and Rehabilitation. Additionally, gabapentin and sodium valproate are also given for diabetic neuropathy pain management. After several clinical evaluations, gabapentin proved a significant pain relief in patients suffering from chronic neuropathic pain.
Other drugs given to treat the condition include dextromethorphan, tramadol, morphine sulfate, and oxycodone. To patients, where oral medications are a concern, topical therapy with capsaicin or transdermal lidocaine are useful. In clinical trials, capsaicin has been proven effective in reducing pain associated with diabetic neuropathic. In some other clinical trials, duloxetine's effects on painful diabetic peripheral neuropathy were studied and showed positive results in the reduction of pain. These increasing clinical trials and changing dynamics are impacting the diabetic neuropathic pain clinical trial landscape significantly.
Diabetic Neuropathic Pain - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of diabetic neuropathic pain drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The diabetic neuropathic pain therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Diabetic Neuropathic Pain - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for diabetic neuropathic pain.Diabetic Neuropathic Pain - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under diabetic neuropathic pain pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Lexicon Pharmaceuticals is conducting a phase II clinical trial for LX9211, which is an orally delivered small molecule compound. Pre-clinical studies showed that the drug was effective for the reduction of neuropathic pain. Moreover, the drug has received fast-track designation from the United States FDA. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic neuropathic pain.Diabetic Neuropathic Pain Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the diabetic neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic neuropathic pain clinical trials:- Bial - Portela C S.A.
- Eli Lilly and Company
- Rigshospitalet, Denmark
- AbbVie
- Swedish Orphan Biovitrum
- NeuraLace Medical, Inc.
- Merck Sharp & Dohme LLC
- Bristol-Myers Squibb
- Nevro Corp
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Lexicon Pharmaceuticals
- Syqe Medical
- Haisco Pharmaceutical Group Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Janssen Pharmaceutical K.K.
- Others
Diabetic Neuropathic Pain - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for diabetic neuropathic paindiabetic neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diabetic neuropathic paindiabetic neuropathic pain drug candidates.Drug: Duloxetine
The trial is designed to assess the safety of duloxetine 60 milligrams daily in patients with diabetic peripheral neuropathic pain. The trial is sponsored by Eli Lilly and Company and is currently under phase III.Drug: ABT-652 6 mg
The objective of the study is to assess the safety of ABT-652 compared to placebo in patients with diabetic neuropathic pain. The trial is sponsored by AbbVie and is currently under phase II.Drug: BVT.115959
Swedish Orphan Biovitrum is developing the drug and is currently under phase II. The study is being conducted to evaluate the safety of BVT.115959 in diabetic patients suffering from neuropathic pain who are not taking analgesics.Reasons To Buy This Report
The Diabetic Neuropathic Pain Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for diabetic neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within diabetic neuropathic pain pipeline insights.Key Questions Answered in the Diabetic Neuropathic Pain - Pipeline Insight Report
- Which companies/institutions are leading the diabetic neuropathic pain drug development?
- What is the efficacy and safety profile of diabetic neuropathic pain pipeline drugs?
- Which company is leading the diabetic neuropathic pain pipeline development activities?
- What is the current diabetic neuropathic pain commercial assessment?
- What are the opportunities and challenges present in the diabetic neuropathic pain drug pipeline landscape?
- What is the efficacy and safety profile of diabetic neuropathic pain pipeline drugs?
- Which company is conducting major trials for diabetic neuropathic pain drugs?
- Which companies/institutions are involved in diabetic neuropathic pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in diabetic neuropathic pain?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Diabetic Neuropathic Pain
4 Patient Profile: Diabetic Neuropathic Pain
5 Diabetic Neuropathic Pain: Epidemiology Snapshot
6 Diabetic Neuropathic Pain: Market Dynamics
7 Diabetic Neuropathic Pain: Key Facts Covered
8 Diabetic Neuropathic Pain, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Diabetic Neuropathic Pain Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Diabetic Neuropathic Pain Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Diabetic Neuropathic Pain Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Diabetic Neuropathic Pain Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Diabetic Neuropathic Pain, Key Drug Pipeline Companies
